WXXWY
WuXi Biologics (Cayman) Inc.
OTC Markets OTCPKUSDEQUITY
DELAYED
Strong buy
+78/100
Last price
14.79
▲ 0.49 (3.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
14.30
Day high
14.79
Day low
14.68
Volume
3.66K
Market cap
—
P/E (TTM)
—
52W range
7.30 – 14.80
Trailing performance
Returnvs SPY
1W
+0.91%
-1.0%
1M
+13.98%
+12.8%
3M
+52.38%
+47.9%
6M
+62.32%
+44.1%
YTD
+80.38%
+66.1%
1Y
+30.35%
+13.9%
3Y
+25.15%
-57.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
6 more panels on WXXWY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $21.79B | $18.68B | $17.03B | $15.27B | +16.7% |
| Operating revenue | $21.79B | $18.68B | $17.03B | $15.27B | +16.7% |
| Cost of revenue | $11.77B | $11.02B | $10.21B | $8.54B | +6.8% |
| Gross profit | $10.02B | $7.65B | $6.83B | $6.72B | +30.9% |
| Research & development | $853.37M | $766.44M | $785.82M | $682.82M | +11.3% |
| Selling, general & admin | $2.31B | $2.15B | $1.79B | $1.43B | +7.7% |
| Total operating expense | $2.96B | $2.68B | $2.38B | $1.93B | +10.6% |
| Operating income | $7.06B | $4.97B | $4.45B | $4.80B | +41.9% |
| Net interest income | $251.52M | $192.78M | $60.69M | $43.09M | +30.5% |
| Pre-tax income | $7.26B | $4.83B | $4.17B | $5.36B | +50.1% |
| Tax provision | $1.52B | $889.03M | $603.18M | $807.87M | +71.4% |
| Net income | $4.91B | $3.36B | $3.40B | $4.42B | +46.3% |
| Net income to common | $4.91B | $3.36B | $3.40B | $4.42B | +46.3% |
| Basic EPS | 2.44 | 1.64 | 1.64 | 2.12 | +48.8% |
| Diluted EPS | 2.32 | 1.56 | 1.54 | 2.02 | +48.7% |
| EBIT | $7.40B | $4.99B | $4.33B | $5.42B | +48.2% |
| EBITDA | $8.85B | $6.43B | $5.50B | $6.22B | +37.6% |
| Basic shares | 2.01B | 2.04B | 2.08B | 2.09B | -1.3% |
| Diluted shares | 2.09B | 2.11B | 2.17B | 2.19B | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.21B | $8.28B | $9.67B | $6.40B | +11.3% |
| Cash & short-term investments | $15.73B | $10.71B | $11.24B | $8.71B | +46.9% |
| Accounts receivable | $7.65B | $5.52B | $5.65B | $4.65B | +38.6% |
| Inventory | $1.38B | $1.52B | $1.77B | $2.28B | -9.2% |
| Total current assets | $28.14B | $23.57B | $21.20B | $18.47B | +19.4% |
| Property, plant & equipment | $29.75B | $28.44B | $29.94B | $25.92B | +4.6% |
| Goodwill & intangibles | $2.00B | $1.97B | $2.04B | $2.08B | +1.3% |
| Total assets | $63.70B | $56.98B | $56.58B | $49.56B | +11.8% |
| Total current liabilities | $8.31B | $8.62B | $7.64B | $9.32B | -3.6% |
| Current debt | $873.52M | $2.44B | $576.33M | $1.32B | -64.1% |
| Long-term debt | $169.38M | $200.90M | $1.57B | $1.46B | -15.7% |
| Total debt | $3.10B | $4.94B | $4.56B | $4.42B | -37.2% |
| Total liabilities | $10.66B | $11.50B | $12.56B | $13.35B | -7.3% |
| Retained earnings | $20.81B | $16.36B | $13.49B | $10.52B | +27.2% |
| Shareholder equity | $47.25B | $41.82B | $40.33B | $35.05B | +13.0% |
| Working capital | $19.83B | $14.95B | $13.56B | $9.15B | +32.6% |
| Net tangible assets | $45.25B | $39.85B | $38.29B | $32.97B | +13.6% |
| Shares issued | 4.13B | 4.11B | 4.26B | 4.23B | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $7.26B | $4.83B | $4.17B | $5.36B | +50.1% |
| Depreciation & amortisation | $1.45B | $1.44B | $1.17B | $800.67M | +0.8% |
| Stock-based compensation | $955.05M | $1.22B | $1.27B | $1.23B | -21.4% |
| Change in working capital | -$1.73B | -$800.50M | -$896.35M | -$974.47M | -116.2% |
| Operating cash flow | $6.34B | $5.22B | $4.67B | $5.54B | +21.5% |
| Capital expenditure | -$3.74B | -$3.93B | -$4.23B | -$5.87B | +4.9% |
| Investing cash flow | -$3.09B | -$3.94B | -$3.23B | -$5.91B | +21.7% |
| Share buybacks | -$1.58B | -$1.77B | -$916.92M | -$2.80B | +10.7% |
| Financing cash flow | -$2.16B | -$2.75B | $1.96B | -$2.59B | +21.3% |
| Free cash flow | $2.61B | $1.29B | $437.20M | -$326.72M | +102.3% |
| End cash position | $9.21B | $8.28B | $9.67B | $6.40B | +11.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $9.21B | $8.44B | +9.2% |
| Cash & short-term investments | $15.73B | $12.54B | +25.5% |
| Accounts receivable | $7.65B | $6.82B | +12.2% |
| Inventory | $1.38B | $1.66B | -16.5% |
| Total current assets | $28.14B | $24.45B | +15.1% |
| Property, plant & equipment | $29.75B | $30.18B | -1.4% |
| Goodwill & intangibles | $2.00B | $1.97B | +1.3% |
| Total assets | $63.70B | $60.44B | +5.4% |
| Total current liabilities | $8.31B | $8.49B | -2.1% |
| Current debt | $873.52M | $2.55B | -65.7% |
| Long-term debt | $169.38M | $185.14M | -8.5% |
| Total debt | $3.10B | $5.11B | -39.2% |
| Total liabilities | $10.66B | $11.37B | -6.3% |
| Retained earnings | $20.81B | $18.70B | +11.3% |
| Shareholder equity | $47.25B | $44.95B | +5.1% |
| Working capital | $19.83B | $15.96B | +24.2% |
| Net tangible assets | $45.25B | $42.98B | +5.3% |
| Shares issued | 4.13B | 4.08B | +1.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.03
+5.44% from price
SMA 20
13.41
+7.61% from price
SMA 50
12.46
+15.83% from price
SMA 100
10.61
+39.45% from price
SMA 200
9.89
+45.86% from price
EMA 12
13.96
+5.93% from price
EMA 26
13.36
+10.67% from price
EMA 50
12.51
+18.22% from price
RSI (14)
64.8
Neutral
MACD (12,26,9)
0.60
Hist 0.06
ATR (14)
0.59
4.09% of price
Realised vol 30D
42.5%
Annualised
Bollinger upper
15.01
20, 2σ
Bollinger lower
11.81
20, 2σ
50 / 200 cross
Golden
12.46 vs 9.89
Trend bias
Above 200
+45.86%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.14
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
42.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.7%
Peak to trough
Max drawdown 5Y
-91.5%
Peak to trough
ATR 14
0.59
4.09% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
GlobeNewswire · 7d ago
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
PR Newswire · 14d ago
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
PR Newswire · 22d ago
Big Pharma Is Pouring Billions Into China’s Biotechs
Barrons.com · 24d ago
WuXi Biologics Reports Strong Profitable Growth in H1 2026
PR Newswire · 44d ago
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
PR Newswire · 51d ago
Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition?
Simply Wall St. · 68d ago
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
PR Newswire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.